Release Date: 16 July 2024
With AFM24, a pioneering tetravalent bispecific IgG1-scFv fusion antibody, Affimed has introduced a game-changing candidate in cancer treatment, representing a cutting-edge innovation in cancer immunotherapy. This novel a...
Release Date: 16 July 2024
Developed by Affimed, Acimtamig signifies a pioneering breakthrough in treating CD30-positive lymphomas. This bispecific antibody, currently in development, targets CD30-positive hematologic tumors. Fueled by Affimed&rsqu...
Release Date: 16 July 2024
Anbenitamab, formerly known as KN026, is a recombinant humanized anti-HER2 bispecific antibody injection co-developed by Shanghai JMT-Bio Technology and Jiangsu Alphamab Oncology for the treatment of HER2-positive solid c...
Release Date: 16 July 2024
Bafisontamab (EMB-01) is a groundbreaking cancer therapy with an innovative mechanism targeting EGFR and c-MET. Developed by Epimab using the FIT-Ig platform, it shares similarities with amivantamab. This bispecific antib...
Release Date: 15 July 2024
Developed by Regeneron, Linvoseltamab (REGN5458) is a BCMA-targeted T-cell engager being studied for the treatment of multiple myeloma. Currently in late-stage clinical studies, Linvoseltamab has already begun to show promise in meeting ...
Release Date: 15 July 2024
Catumaxomab, known as the first bispecific antibody, has a long history in immunotherapy. Despite problems that led to its withdrawal, its development and subsequent market presence were critical in changing the landscape of bispecific a...
Release Date: 15 July 2024
MedImmune’s Volrustomig (MEDI5752) is a new bispecific antibody that targets the immunological checkpoints programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte associated protein 4 (CTLA-4). Following t...
Release Date: 15 July 2024
Tarlatamab emerges as a pioneering force in the changing landscape of oncology, representing the first-in-class bispecific T-cell Engager (BiTE) therapy targeting delta-like ligand 3 (DLL3) developed for the treatment of ...
Release Date: 15 July 2024
Targeting certain molecular markers has become an important method in cancer therapies, and one such marker that has received a lot of interest is the human epidermal growth factor receptor 2 (HER2). Overexpression of HER...
Release Date: 15 July 2024
In the realm of cancer therapeutics, MCLA-129 emerges as a novel and promising candidate, developed by Merus to address solid cancers. This human, EGFR/c-MET Biclonic bispecific antibody boasts a unique design, incorporat...
Release Date: 14 July 2024
TRAF2 and NCK-interacting protein kinase (TNIK) is a serine/threonine kinase protein that has emerged as a promising therapeutic target across a spectrum of diseases, ranging from cancer to neurological disorders and infl...
Release Date: 14 July 2024
RAF genes, such as BRAF, are essential for controlling cell growth and division. Changes in these genes can result in abnormal cell growth, which can contribute to the formation of different types of cancers, including br...
Release Date: 14 July 2024
MKK4 (mitogen-activated protein kinase kinase 4; also known as MEK4) is a crucial signaling molecule involving in various cellular processes, offering therapeutic potential across a spectrum of diseases. Its normal functi...
Release Date: 14 July 2024
UDP-3-O-((R)-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) serves as a critical enzyme in the biosynthesis of lipid A, an essential component of the outer membrane of Gram-negative bacteria. Its role in lipid...
Release Date: 14 July 2024
LRRC15, also known as leucine-rich repeat-containing protein 15, stands as a promising protein target within the realm of biomedical research. This multifaceted protein, characterized by its leucine-rich repeats, plays a ...